Braidwell LP Acquires Shares of 612,841 Amylyx Pharmaceuticals

Hedge fund buys significant stake in biotech company developing new neurological treatments

Mar. 15, 2026 at 8:57am

Got story updates? Submit your updates here. ›

Braidwell LP, a hedge fund, has acquired 612,841 shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), a biopharmaceutical company focused on developing treatments for rare and debilitating neurological diseases. The purchase, valued at approximately $8.3 million, represents a 0.56% ownership stake in Amylyx Pharmaceuticals.

Why it matters

Amylyx Pharmaceuticals is a promising biotech company with a lead product candidate, AMX0035, that is currently under review by the FDA for the treatment of amyotrophic lateral sclerosis (ALS). The acquisition by Braidwell LP suggests the hedge fund sees significant potential in Amylyx's pipeline and future growth prospects.

The details

According to a filing with the Securities and Exchange Commission, Braidwell LP purchased the 612,841 shares of Amylyx Pharmaceuticals during the third quarter of 2025. This represents a 0.56% ownership stake in the company. Amylyx Pharmaceuticals is developing small-molecule therapies designed to protect neurons and support cellular health in patients with neurological conditions that currently have limited or no disease-modifying treatment options.

  • Braidwell LP acquired the 612,841 shares of Amylyx Pharmaceuticals during the third quarter of 2025.

The players

Braidwell LP

A hedge fund that has acquired a significant stake in Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing treatments for rare and debilitating neurological diseases, including a lead product candidate AMX0035 that is under review by the FDA for the treatment of ALS.

Got photos? Submit your photos here. ›

The takeaway

The acquisition of a 0.56% stake in Amylyx Pharmaceuticals by Braidwell LP suggests the hedge fund sees significant potential in the biotech company's pipeline of neurological treatments, particularly its lead candidate AMX0035 for ALS. This investment highlights the growing interest and optimism around Amylyx's efforts to address unmet needs in the rare disease space.